Each year, on 11th February, the United Nations and the global scientific community celebrate the International Day of Women and Girls in Science. Women are underrepresented in science and are...
Read More
A new government will mean new Health & Social care policy; reorganisations may follow and funding will most definitely be impacted. We are in a time of great change in...
Read More
Nine of our senior team made the trip to Copenhagen to represent Mtech Access at ISPOR Europe this November. The conference brought together leading experts from across Health Economics and Outcomes...
Read More
Our expert developers work with our health economists, medical writers and market access consultants to create Veeva‑compatible digital communication tools, including payer toolkits, budget impact models, and other data visualisations....
Read More
We understand that the path to successful global market access and uptake is complex and multi-faceted. Defining robust pricing and market access strategies, and developing meaningful value strategies, are essential...
Read More
We invited Pharma market access professionals to a seminar on 25th September 2019 at the Royal College of Physicians in London to hear directly from speakers who work in and...
Read More
Introducing David Thorne Director of NHS Insights & Interaction Originally a nurse, David has occupied board-level positions within both NHS hospitals and commissioning organisations. He was previously the Chief Executive...
Read More
Following the acquisition of Blue River Consulting we are pleased to announce that MD and owner David Thorne will be heading-up our NHS insights and interaction services at Mtech Access, bringing unparalleled hands-on experience and…
In order to comply with the EU regulation on medical devices, the regulatory stage Clinical Evaluation Report (CER) has been the focus of renewed attention by the medical device industry....
Read More
Partitioned survival analysis (PartSA) is currently the most commonly used modelling approach within HTA (health technology assessment) for advanced or metastatic cancers. However, until recently, there was no formal documentation...
Read More
